Dabrafenib (Tafinlar®)

Assessment Status NCPE Assessment Process Complete
Drug Dabrafeib
Brand Tafinlar®
Indication For the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation.
Assessment Process
Rapid review commissioned 11/09/2013
Rapid review completed 02/10/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 03/12/2013
NCPE assessment completed 24/06/2014
NCPE assessment outcome The NCPE considers dabrafenib (Tafinlar®) to be cost effective compared to vemurafenib.